Skip to content

Comparative response evaluation of Cisplatin-Capecitabine with Cisplatin-5-Fluorouracil in advanced gastric carcinoma.

Comparative response evaluation of Cisplatin-Capecitabine with Cisplatin-5-Fluorouracil in advanced gastric carcinoma.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20170715001
Enrollment
62
Registered
2017-07-15
Start date
2017-07-20
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinically diagnosed and histopathologically proved advanced gastric carcinoma (AJCC Stage IV). Advanced gastric carcinoma.

Interventions

Cisplatin 80 mg/m2 as a 2 hour i.v. infusion on day 1 with proper hydration plus 5&#45
FU 800 mg/m2/day by continuous infusion on days 1–5 every 3 weeks.,Cisplatin 80 mg/m2 as a 2 hour i.v. infusion on day 1 with proper hydration plus Oral Capecitabine 1000 mg/m2 twice daily on days 1
Active Comparator Drug,Active Comparator Drug
Cisplatin plus 5&#45
Fluorouracil,Cisplatin plus Capecitabine

Sponsors

Bangabandhu Sheikh Mujib Medical University
Lead Sponsor
Dr. Ariful Hoque
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Clinically diagnosed and histopathologically proved advanced gastric carcinoma (AJCC Stage IV). 2.At least one measurable lesion, no prior chemotherapy or radiotherapy. 3.Patients with Eastern Cooperative Oncology Group(ECOG) performance status up to 2. 4.Patients within the age limits of 18 to 70 years. 5.Presence of adequate renal, hepatic and cardiac function. Adequate renal function was defined as an estimated Creatinine Clearance Rate ≥60 ml/min using the Cockcroft and Gault formula. Adequate hepatic function was defined as Serum bilirubin ≤1.5 mg/dl, Serum transaminases ≤3 × upper normal limit or ≤5 × upper normal limit in cases of hepatic metastases).

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating women. 2.Serious concomitant medical illness including clinically significant cardiovascular disease, uncontrolled diabetes mellitus or hypertension. 3.Evidence of central nervous system metastases. 4.Major surgery of trauma in the previous four weeks.

Design outcomes

Primary

MeasureTime frame
Tumor size Every six weeks Clnical examination and Imaging tests.,Site and number of metastasis Every six weeks Imaging tests.,Pain Every three weeks Wong-Baker FACES Pain Rating Scale

Secondary

MeasureTime frame
Hemoglobin percentage and Neutrophil count Every three weeks Laboratory tests.,Hepatotoxicity and nephrotoxicity Every three weeks Liver and Renal function tests

Countries

Bangladesh

Contacts

Public ContactAriful Hoque

Bangabandhu Sheikh Mujib Medical University

arifulh7@gmail.com8801818619826

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026